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Abstract 27 
Deregulated expression of the type I cytokine receptor, CRLF2, is observed in 5-15% 28 
of precursor B-cell acute lymphoblastic leukaemia (B-ALL). We have previously 29 
reported the genomic landscape of patients with CRLF2 rearrangements (CRLF2-r) 30 
using both whole genome and exome sequencing, which identified a number of 31 
potential clonal and sub-clonal genomic alterations. In this study, we aimed to assess 32 
when the CRLF2-r; IGH-CRLF2 or P2RY8-CRLF2, arose during the evolution of both 33 
Down syndrome-ALL (DS-ALL) and non-DS-ALL. Using fluorescence in situ 34 
hybridisation, we were able to track up to four structural variants in single cells from 35 
47 CRLF2-r B-ALL patients, which in association with our multiplex single cell analysis 36 
of a further four patients, permitted simultaneous tracking of copy number 37 
alterations, structural and single nucleotide variants within individual cells. We 38 
observed CRLF2-r arising as both early and late events in DS and non-DS-ALL patients. 39 
Parallel evolution of discrete clones was observed in the development of CRLF2-r B-40 
ALL, either involving the CRLF2-r or one of the other tracked abnormalities. In depth 41 
single cell analysis identified both linear and branching evolution with early clones 42 
harbouring a multitude of abnormalities, including the CRLF2-r in DS-ALL patients.  43 
 44 
 45 
 46 
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Introduction 49 
Acute lymphoblastic leukaemia (ALL) is defined by primary chromosomal 50 
abnormalities that drive disease development and progression and are strongly 51 
associated with outcome (1). However, the impact of sub-clonal architecture, 52 
including structural variants and mutations, is not as well defined. Initial insights into 53 
secondary genetic changes were gained through the study of monozygotic twins in 54 
which either one or both children developed ALL (2-5). These investigations identified 55 
an in utero origin of ALL. In particular, pre-leukaemic clones were found to harbour 56 
the ETV6-RUNX1 fusion, which required additional abnormalities after birth to lead to 57 
overt leukaemia. Key features of the sub-clonal architecture of these cases suggested 58 
a Darwinian natural selection model to describe the process through which leukaemia 59 
presents, progresses and evades treatment (2, 3, 6).   60 
Initiating genomic abnormalities have not been described in all subgroups of B-lineage 61 
ALL (B-ALL). A particular subtype, known as Ph-like/BCR-ABL1-like ALL, constitutes 10-62 
15% of B-ALL (7, 8). It is characterised by; a transcriptional profile similar to BCR-ABL1 63 
driven disease; high expression of the type I cytokine receptor, cytokine receptor-like 64 
factor 2 (CRLF2); the presence of tyrosine kinase activating fusion genes and mutations 65 
of genes within the JAK/STAT and RAS signalling pathways (9). Deregulation of CRLF2 66 
occurs via two genomic alterations (IGH-CRLF2, P2RY8-CRLF2) resulting in its 67 
overexpression, however on their own they are insufficient to cause overt leukaemia 68 
(10-12). It is well documented that copy number alterations of genes involved in B-cell 69 
differentiation and cell cycle control (10, 13-15), including PAX5, IKZF1 and CDKN2A, 70 
and mutations of kinases or receptor encoding genes (9, 16), in particular CRLF2, JAK2 71 
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and IL7R, are common in this subtype of B-ALL. However, data indicating whether 72 
CRLF2-rearrangements (CRLF2-r) are early and/or sub-clonal event are scarce (17, 18).  73 
Evidence of intratumoral heterogeneity has been revealed by a range of techniques, 74 
including conventional cytogenetics (19) and fluorescence in situ hybridisation (FISH) 75 
(20). Next generation sequencing technologies have exposed remarkable complexities 76 
in the genomic landscape of leukaemic blasts (21); coupling this approach with single 77 
cell analysis revealed additional multiple levels of heterogeneity that may further 78 
inform of treatment failure, resistance and subsequent relapse (22, 23). 79 
In this respect, we have previously developed a multiplex Q-PCR method to target 80 
patient specific DNA alterations in flow-sorted single leukaemic cells using the 81 
BioMark HD microfluidics platform (23). This approach allows the simultaneous 82 
detection of structural variants (SVs), including translocations and fusion genes, copy 83 
number alterations (CNAs) and single nucleotide variants (SNVs) within a single cell 84 
that can be combined to illustrate clonal evolution within a bulk sample (20, 24, 25).  85 
We have previously reported the genomic landscape of 11 CRLF2-r patients, using 86 
both whole genome (WGS) and exome sequencing (WES) (26), which identified a 87 
number of potential driver genomic alterations in each case. Both read counts and 88 
variant allele frequencies varied, suggesting that some aberrations were sub-clonally 89 
distributed, whilst others were clonal. In this study, we aimed to assess at what time 90 
point the CRLF2-r; IGH-CRLF2 or P2RY8-CRLF2, arose in the evolution of both Down 91 
syndrome-ALL (DS-ALL) and non-DS-ALL. Using FISH, we were able to track up to four 92 
SVs in single cells from 47 CRLF2-r ALL patients, which in association with multiplex 93 
single cell analysis of a further four patients, has permitted simultaneous tracking of 94 
CNAs, SVs and SNVs within single cells.  95 
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In this study, we have observed CRLF2-r arising as both early and late events in DS and 96 
non-DS-ALL. Parallel evolution of discrete clones was observed in the development of 97 
CRLF2-r ALL, either involving the CRLF2-r or one of the other tracked abnormalities. In 98 
depth single cell analysis identified both linear and branching evolution with early 99 
clones harbouring a multitude of abnormalities, including the CRLF2-r in DS-ALL.  100 
 101 
Methods 102 
Sample Cohort 103 
Patients with a CRLF2-r detectable by FISH or Multiplex Ligation-dependent Probe 104 
Amplification (MLPA) with available material were selected from six ALL treatment 105 
trials: UKALL97/99, n=24; UKALL2003, n=16; UKALLXI, n=2; UKALLXII, n=6; UKALLR3, 106 
n=1; ALL-BFM 2000, n=2 (Supplementary Table 1). Ages ranged from 1-54 years 107 
(median 5 years, mean 9.73 years).  108 
Institutional review board approval was obtained at each of the collaborating centres. 109 
Informed consent was obtained in accordance with the Declaration of Helsinki.  110 
Genomic target selection 111 
WGS and WES data for the patients included in this study have been previously 112 
published (26). We used these data to identify SVs, which could be tracked in single 113 
cells by FISH and focal CNAs and SNVs for tracking in single cells by multiplex Q-PCR. 114 
Two DS-ALL patients (19599, 11538) and two non-DS-ALL patients (11543, 21819) 115 
were investigated by single cell multiplex Q-PCR(23). SVs tracked in each patient by 116 
FISH are shown in Supplementary Table 1 and SVs, CNAs and SNVs tracked by Q-PCR 117 
are shown in Supplementary Tables 2 and 3. 118 
Xenograft transplants 119 
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All in vivo studies were performed by personnel holding a current Personal Licence 120 
under the Animals (Scientific Procedures) Act 1986 and were conducted in line with 121 
current Home Office regulations, compliant with the 3R principles (Home Office 122 
license number PPL 60/4552). No further ethical approval was required. Animals were 123 
housed under pathogen free conditions, and all experimental manipulations were 124 
performed on anaesthetized mice under sterile conditions in a laminar flow hood.  125 
Male and female NSG mice (Jax® mice strain name: NOD.Cg-Prkdcscid Il2rgtm1wjl/SzJ) 126 
were transplanted with 1x106 patient primary bone marrow cells, injected 127 
intrafemorally into the right femur, as previously described (27). Animals were 128 
maintained until they showed clinical signs (weight loss, palpable spleen), which 129 
necessitated humane killing (range 3-10 months post injection). Patient-derived 130 
xenograft cells (PDXs) from the bone marrow and spleen were harvested, passed 131 
through cell strainers (0.40µm) and frozen for long term storage in 90% foetal calf 132 
serum and 10% DMSO in liquid nitrogen. 133 
Cytogenetics and fluorescence in situ hybridisation 134 
Fixed cells were available for 47 CRLF2-r patients (46 at diagnosis and 1 at relapse): 14 135 
patients were DS (P2RY8-CRLF2, n=12; IGH-CRLF,2 n=2) and 33 were non-DS (P2RY8-136 
CRLF2, n=25; IGH-CRLF2, n=8) (Supplementary Table 1). Where possible, direct fixed 137 
cell cultures were tested to prevent discrepancies caused by outgrowth of normal cells 138 
and death of malignant cells. Multiple colour interphase FISH was used to assess the 139 
simultaneous presence of both CRLF2-r (XX-87136C11, XX-82904A1, RP4-674K4, RP11-140 
309C18)(10) and deletions of CDKN2A/B (RP11-149I2) and/or PAX5 (RP11-469D03) 141 
and/or IKZF1 (G248P800745C8/WI2-3001F15) (previously identified by MLPA and 142 
single nucleotide polymorphism (SNP) arrays (26)) in the same cell, as previously 143 
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reported (10, 28). Briefly, home-grown FISH probes were mixed 1:1 with hybridisation 144 
buffer (company) and denatured at 75°C for five minutes followed by hybridisation at 145 
37°C overnight. Coverslips were removed in 2x SSC and slides washed in 0.02% SSC 146 
with 0.003% NP40 at 72°C for two minutes followed incubation in 0.1% SSC at room 147 
temperature for two minutes.  Slides were mounted with 10ul DAPI (Vector 148 
laboratories, California, USA). Automated capture and scoring was performed using 149 
an automated Olympus BX-61 8-bay stage florescence microscope with a x60 oil 150 
objective. Images were stored and analysed using the CytoVision 7.2 SPOT counting 151 
system (Leica Microsystems, Gateshead, UK). Where possible, more than 100 nuclei 152 
were scored for each FISH test by two independent analysts. A cut-off threshold of 153 
>8% was used for all multiple colour probe combinations to allow for interference and 154 
obscuring of signals. The cut-off level was established by counting the number of 155 
abnormal (false positive) signals generated when the multiple colour probe 156 
combinations were hybridised to normal cells. 157 
Commercial and custom primers for Q-PCR and digital PCR 158 
We aimed to track all identified somatic SVs and SNVs detected by WGS and WES 159 
encompassing those present at high and low variant allele frequencies; some could 160 
not be tracked due to the sequence surrounding the rearrangement (Supplementary 161 
Tables 2 and 3).    162 
Custom Taqman Q-PCR assays for SV or SNP that could distinguish the mutant allele 163 
from its wild-type counterpart were designed as previously described (23). DNA copy 164 
number Taqman assays were purchased from Applied Biosystems. Three CNA assays 165 
were chosen within each DNA target region of interest and the diploid reference 166 
region encompassing B2M (Supplementary Table 4). 167 
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FACS for single cell collection 168 
Diagnostic patient samples and those previously harvested from xenograft transplants 169 
were thawed from liquid nitrogen and bulk cells were labelled with carboxyfluorescin 170 
diacetate, succinimidyl ester (CFSE) and 6 diamidino-2-phenylindole (DAPI) to identify 171 
live and dead cells, respectively. Cells retrieved from successful transplantations into 172 
NSG mice were also labelled with phycoerythrin (PE)–conjugated anti-human CD45 173 
and allophycocyanin (APC)–conjugated anti-mouse CD45 antibodies (BD Biosciences) 174 
before resuspension in PBS and DAPI in order to identify and sort the human 175 
leukaemic cells. 176 
Single Cell Sorting and multiplex Q-PCR analysis 177 
Single cell sorting was carried out after staining, according to our established protocol, 178 
as previously described (23). Briefly, single cells were sorted from each case into 179 
individual wells of a 96 well plate and lysed.  The DNA target region of interest, 180 
including patient specific gene fusions, SNVs and CNAs, was amplified. We collected 181 
252-336 cells from the diagnostic ALL samples, 81-252 cells from PDX and 48 cord 182 
blood cells (normal diploid control). A cell was called positive for a SNP (or SNV) if the 183 
Q-PCR cycle threshold (CT) value was below 28. We used a modified version of the 184 
ΔΔCT method (Applied Biosystems, Life Technologies Ltd.) to integrate results from 185 
multiple Taqman assays targeting the same region to determine the relative copy 186 
number for each locus. The use of multiple assays to target one region increased the 187 
accuracy of attributed CNAs. The resulting reaction mix was then diluted and Q-PCR 188 
completed using the 96x96 dynamic array and the BioMark HD from Fluidigm.  189 
Several approaches were adopted during this experiment to optimise and confirm the 190 
presence of single cells and ensure that all assays performed efficiently under 191 
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experimental conditions (23). Assay error rates in these experiments were zero. Single 192 
cell data removed from the Q-PCR analysis included those from wells with no data (no 193 
cell) and those wells in which all B2M assays did not have a strong signal (<25 CT). On 194 
average this accounted for the removal of ~9% of data points. Only mutational spectra 195 
occurring in more than one cell were included in the analysis. 196 
Results 197 
To explore whether IGH-CRLF2 and P2RY8-CRLF2 were early or late events in the 198 
evolution of B-ALL, we performed multiple colour FISH on 47 ALL patient samples to 199 
track the CRLF2-r (IGH-CRLF2, n=10, P2RY8-CRLF2, n=37) and deletions common in 200 
ALL: IKZF1 and/or CDKN2A/B and/or PAX5.  201 
IGH-CRLF2 is an early event in B-ALL 202 
In those patients with IGH-CRLF2 bone marrow blast counts at diagnosis correlated 203 
with the percentage of abnormal blasts detected by multiple colour FISH 204 
(Supplementary Table 1), suggesting that the tracked abnormalities were present in 205 
the major leukaemic clone. In 80% (8/10), IGH-CRLF2 was a clonal event, either 206 
presenting first in the majority of cells in four patients, or together with other tracked 207 
abnormalities in four patients (examples of FISH signal patterns are shown in Figures 208 
1A and 1B).   209 
P2RY8-CRLF2 is an early event in B-ALL  210 
In 73% (27/37) of patients with P2RY8-CRLF2, the bone marrow blast counts at 211 
diagnosis correlated with the percentage of abnormal blasts detected by multiple 212 
colour FISH (Supplementary Table 1). P2RY8-CRLF2 presented as the first tracked 213 
abnormality in 9/27 patients and together with other abnormalities in 18/27 patients 214 
(for one case only relapse material was available; 6897) (examples of FISH signal 215 
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patterns are shown in Figures 1C and 1D).  216 
CRLF2-r are observed as sub-clonal events in B-ALL 217 
While most patients with IGH-CRLF2 have the rearrangement as an early event in 218 
leukaemogenesis, in two IGH-CRLF2 patients (3789 and 3141), loss of IKZF1 was 219 
detected as the earliest event with IGH-CRLF2 observed only in a sub-clone (example 220 
from patient 3789 is shown in Figure 2A). Patient 3141 had two subsequent relapses; 221 
at second relapse, the IKZF1 deletion was present in 64% of cells compared to 33% for 222 
IGH-CRLF2 as assessed by individual FISH tests (data not shown). These data confirm 223 
the sub-clonal nature of IGH-CRLF2 in this patient.  224 
Similarly, the sub-clonal nature of P2RY8-CRLF2 was observed in 24% (9/37) of the 225 
patients, where the percentage of abnormal cells detected by FISH was notably less 226 
than the blast count at diagnosis, suggesting that the earliest events remained 227 
undetected in these patients (Supplementary Table 1). Of particular interest was 228 
patient 2017, where monoallelic loss of CDKN2A/B and PAX5 preceded the formation 229 
of the fusion (Figure 2B). Of the two or three abnormalities tracked by FISH, P2RY8-230 
CRLF2 presented first in 4/9 patients and together with other abnormalities in 5/9 231 
patients.  232 
Parallel evolution occurs in the development of CRLF2-r ALL 233 
In five P2RY8-CRLF2 patients, evidence of parallel evolution of cells containing 234 
abnormalities of one or more genes was observed (Figure 3A-E). In three patients 235 
(12200, 3173, 4954), four sub-clones were identified. In patients 12200 and 3173, 236 
(Figure 3A and B, respectively), clones harbouring either the P2RY8-CRLF2 fusion or 237 
loss of CDKN2A/B or IKZF1, respectively, occurred in sub-clones. The main clone seen 238 
at diagnosis must have evolved from a cell that acquired both abnormalities giving it 239 
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a competitive advantage over the other sub-clone. In patient 4954 (Figure 3C), the 240 
P2RY8-CRLF2 fusion was present together with either, loss of one or two copies of 241 
CDKN2A/B and loss of one copy of IKZF1. These data suggest that CDKN2A/B 242 
undergoes deletions in independent sub-clones.  The main clone seen at diagnosis 243 
must have evolved from a cell that acquired all three abnormalities giving it a 244 
competitive advantage over the other sub-clone.  245 
In patients 20753 and 5817, the parallel clones were defined by the CRLF2-r. In patient 246 
20753 (Figure 3D), one sub-clone gained an extra P2RY8-CRLF2 fusion with subsequent 247 
loss of a single copy of PAX5 prior to the loss of the second copy of IKZF1. In patient 248 
5817 (Figure 3E), the sub-clones harboured either a CRLF2-r with loss of one copy of 249 
IKZF1 (9%) or P2RY8-CRLF2 alone (17%). Identical parallel evolution was found in 250 
patient 21572 (Figure 3F). The parallel clones were defined by an IGH-CRLF2 251 
translocation alone or a CRLF2-r coupled with loss of one copy of IKZF1. Together these 252 
data suggest the sub-clonal architecture observed in these cases could only have 253 
occurred if IKZF1 and/or CDKN2A/B undergo deletions in independent sub-clones. 254 
Single cell multiplex Q-PCR identified linear and branching development of CRLF2-r 255 
ALL 256 
Whilst FISH allowed the detection of a small number of large SVs, it was not possible 257 
to investigate associations between small CNAs and SNVs. Single cell multiplex Q-PCR 258 
allowed a more comprehensive analysis of four patients. Individual cells were sorted 259 
from the leukaemia sample and assayed by multiplex Q-PCR for the presence of 260 
specific genetic aberrations previously identified from WGS and WES (26). A similar 261 
assessment was carried out using unsorted PDX ALL cells from the same patients in 262 
order to determine self-renewal properties of discrete clones.  From these samples 263 
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and expanded single cell data, we were able to define detailed clonal architectures in 264 
which genetically distinct sub-clones were characterised by SVs, SNVs and CNAs 265 
(Figure 4).   266 
In non-DS-ALL patients 11543 and 21819 a linear architecture was observed (Figure 267 
4A and B). In patient 11543 (Figure 4A) the IGH-CRLF2 translocation was secondary to 268 
multiple CNAs and SNVs, including an initial IKZF1 deletion, with a second IKZF1 269 
deletion occurring after the acquisition of the IGH-CRLF2 translocation. The 270 
architecture was recapitulated in both xenograft bone marrow and spleen cells, 271 
suggesting that all sub-clones possessed self-renewal properties. In patient 21819 272 
(Figure 4B) the P2RY8-CRLF2 fusion was secondary to loss of IKZF1 and CDKN2A (Figure 273 
4C). Serial xenograft transplants were ultimately populated by the major P2RY8-CRLF2 274 
containing clone seen at diagnosis.  275 
In contrast, the two DS-ALL patients, 19599 and 11538, showed a branching sub-clonal 276 
architecture where the CRLF2-r was one of several structural alterations that defined 277 
the earliest identified clone (Figure 4C and D).  In patient 19599 (Figure 4C) the sub-278 
clonal architecture was defined by discrete IKZF1 and JAK2 mutations. A single evolved 279 
clone from the diagnostic sample engrafted into both spleen and bone marrow of 280 
transplanted mice, suggesting that the other sub-clones had a reduced self-renewal 281 
ability. In patient 11538 (Figure 4D) the sub-clonal architecture was defined by 282 
multiple IKZF1 events and additional mutations that were secondary to the P2RY8-283 
CRLF2 fusion. Whilst the architecture was recapitulated in the xenograft, the major 284 
clones at diagnosis were present as minor clones in the xenografts. 285 
Whilst multiple mice were not analysed by single cell QPCR for each sample, FISH was 286 
completed and showed comparable results (data not shown). 287 
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 288 
Discussion  289 
In several blood cell cancers there appears to be a preferential order of mutations, 290 
including in ALL (20, 21, 29, 30), AML (31) and MDS (32-34). To determine whether 291 
IGH-CRLF2 and P2RY8-CRLF2 were early or late events in the evolution of B-ALL, we 292 
carried out single cell analysis using both FISH and multiplex Q-PCR of 51 DS and non-293 
DS-ALL patients. Forty-seven were investigated by FISH for specific rearrangements 294 
including P2RY8-CRLF2 or IGH-CRLF2 coupled with deletions of IKZF1, PAX5 or 295 
CDKN2A/B. The remaining four cases underwent a more detailed analysis using 296 
multiplex Q-PCR for multiple patient specific SVs, SNVs and CNAs. 297 
CRLF2-r were observed as common early events in the majority of patients studied, 298 
including DS and non-DS-ALL patients. However, the P2RY8-CRLF2 fusion was also 299 
found to be sub-clonal in approximately one quarter of patients investigated. The sub-300 
clonal nature of the P2RY8-CRLF2 fusion has previously been reported (17). In 301 
contrast, the early nature of both IGH-CRLF2 and P2RY8-CRLF2 in DS-ALL was recently 302 
reported, where 92% (11/12) of patients retained these rearrangements at relapse. 303 
The authors suggested that both rearrangements were early events in 304 
leukaemogenesis which may play important roles at relapse (18). However, other 305 
evidence suggests that relapse in ALL can originate from sub-clones distributed 306 
anywhere in the phylogenetic architecture of the cancer (20, 35-37), indicating that 307 
the preservation of any individual genetic lesion in relapse does not necessarily reflect 308 
a founder , early or truncal status. 309 
In the present study, six patients showed the potential development of two 310 
independent leukaemias with clones showing parallel evolution driven by reiterative 311 
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CNAs within the same genes. In three patients with P2RY8-CRLF2 loss of one copy of 312 
the other tracked gene occurred in discrete populations. The bulk of the leukaemia 313 
then evolved from a cell acquiring both abnormalities.  In the remaining three patients 314 
the parallel clones were defined by distinct early CRLF2-r. The presence of reiterative 315 
genetic changes has been reported in ALL before (20, 38) and they are thought to arise 316 
by RAG-mediated mutagenesis (22). Reiterative mutation is a relatively common 317 
feature in other cancers (39) reflecting convergent (or parallel) evolution in the 318 
context of common selective pressures. It is also important to consider that we are 319 
analysing one sample at a single time point in the development of this disease. It is 320 
not always possible to determine the precise temporal order in which events take 321 
place during tumour development unless representative populations of all ancestral 322 
clones remain at diagnosis. In those where we observed the CRLF2-r and deletions of 323 
other genes as the earliest identifiable events, it is possible that they arose 324 
sequentially with the earliest events no longer being present at diagnosis. The limited 325 
sensitivity of FISH for detecting these rare clones impacts how precise we can be in 326 
mapping the temporal order of tumour development.   327 
Sub-clonal heterogeneity and clonal selection has been studied in many 328 
haematological diseases, highlighting the importance of understanding sub-clonal 329 
architecture in relation to therapeutic decisions regarding individual patients (38, 40, 330 
41). Single cell multiplex Q-PCR in two DS-ALL patients revealed the presence of IGH-331 
CRLF2 or P2RY8-CRLF2 in the earliest clone, together with a multitude of SNVs and 332 
other CNAs. These patients showed a complex branching tree structure with 333 
reiterative deletions and mutations occurring in different sub-clonal populations. In 334 
contrast, the leukaemia in the two non-DS-ALL patients appeared to evolve in a linear 335 
15  
non-branching manner with IGH-CRLF2 or P2RY8-CRLF2 occurring on a background of 336 
SNVs or CNAs and arising later in leukaemia development. These data suggest that 337 
IGH-CRLF2 and P2RY8-CRLF2 could be earlier events in DS-ALL compared to non-DS-338 
ALL. Although our results suggest that there is no difference between DS and non-DS 339 
ALL, we are - despite simultaneously tracking several alterations - still likely 340 
underestimating the complexity of clonal phylogeny.  341 
The application of single cell Q-PCR to PDX cells demonstrated that in three of the four 342 
patients, the majority of clones identified at diagnosis had leukaemia propagating 343 
capacity, being present in both bone marrow and spleen in primary and second 344 
generation mice. In the PDX cells from patient 19599, only one sub-clone engrafted, 345 
suggesting that either the other sub-clones did not have self-propagating capacity, or 346 
that they were below the level of detection within the diagnostic sample. Such findings 347 
have been previously reported, in which analysis of CNAs from mice injected with as 348 
few as 100 cells remained highly related to the diagnostic sample, with only a few 349 
novel deletions arising in the primary mice (42). In some samples, clonal outgrowth of 350 
the dominant diagnostic clone was observed; however, in others they observed 351 
outgrowth of sub-clones (42). The outgrowth of certain clones would not necessarily 352 
mean the clones that are no longer present are incapable of self-renewal, but are less 353 
suited to the murine environment.   354 
Evolution of cancer was initially assumed to be driven by a steady accumulation of 355 
genomic abnormalities over time. However, others have suggested that the presence 356 
of explosive changes caused by global genomic instability (43), a chromothripsis event 357 
(44) or the effect of a single high impact mutation (45, 46) may be responsible. 358 
Previous work has postulated that additional copies of chromosome 21 can promote 359 
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genomic instability (47, 48). Interestingly, among the four patients studied here by 360 
multiplex Q-PCR, three showed a large number of abnormalities in the earliest clone 361 
(range 11-20), suggesting that either a single or series of explosive events may have 362 
occurred creating a backbone of aberrations upon which further evolution could take 363 
place. Notably these three patients had either constitutional or somatic gain of 364 
chromosome 21 either. 365 
In summary, our data indicates that CRLF2-r co-operate with multiple additional 366 
genetic alterations in ALL and that there appears to be no major restraint on whether 367 
CRLF2-r arise early as a founder or truncal event or later in clonal evolution. 368 
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Figure Legends 538 
Figure 1. Multiple colour FISH showing examples of IGH-CRLF2 as a clonal event 539 
arising (A) first or (B) together with other tracked abnormalities (C) P2RY8-CRLF2 as 540 
a clonal event arising first or (D) together with other tracked abnormalities. 541 
• Representative FISH images on the right show examples of each leukaemic 542 
sub-clone. 543 
• Leukaemic sub-clone percentages for the diagnostic samples are indicated 544 
next to each clone and only include populations above the 8% cut off.  545 
• Dotted clone with “?”: presumed but undetected founder clone. 546 
 (A) For patient 23394 a total of 245 abnormal nuclei at diagnosis were scored for 547 
probes to CRLF2 (red/green) and CDKN2A/B (gold). In 34% of nuclei the IGH-CRLF2 548 
translocations was an early event observed in the presence of two copies of 549 
CDKN2A/B. This clone evolves into two sub-clones: one gains an extra copy of IGH in 550 
17% of nuclei; one loses a single copy of CDKN2A/B in 49% of nuclei. 551 
(B) For patient 4001 a total of 129 abnormal nuclei at diagnosis were scored for probes 552 
to CRLF2 (red/green), IKZF1 (gold) and PAX5 (aqua). In 67% of nuclei the IGH-CRLF2 553 
translocation was present with one copy of IKZF1 and two copies of PAX5. This clone 554 
evolves with loss of a single copy of PAX5 in 33% of nuclei.  555 
(C) For patient 10924 a total of 227 abnormal nuclei at diagnosis were scored for 556 
probes to CRLF2 (red/green) and IKZF1 (gold). In 11% of nuclei the P2RY8-CRLF2 fusion 557 
is an early event before the loss of a single copy of IKZF1 observed in the bulk 558 
leukaemic clone at 89%.  559 
(D) For patient 322 a total of 70 abnormal nuclei at diagnosis were scored for probes 560 
to CRLF2 (red/green) and CDKN2A/B (gold). In 67% of nuclei the P2RY8-CRLF2 fusion 561 
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and loss of a single copy of CDKN2A/B present together. A further 33% of cells gained 562 
an additional copy of the CRLF2 probe, which usually indicates the presence of an 563 
additional sex chromosome (+X/Y). 564 
 565 
 566 
 567 
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 570 
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Figure 2. Multiple colour FISH showing examples of the sub-clonal nature of (A) 585 
P2RY8-CRLF2 (B) IGH-CRLF2 586 
• Representative FISH images on the right show examples of each leukaemic 587 
sub-clone. 588 
• DAPI has been removed from panel B in order for the PAX5 aqua signals to be 589 
observed.   590 
• Leukaemic sub-clone percentages for the diagnostic samples are indicated 591 
next to each clone and only include populations above the 8% cut off.  592 
• Dotted clone with “?”: presumed but undetected founder clone. 593 
(A) For patient 3789 a total of 144 abnormal nuclei at diagnosis were scored for probes 594 
to CRLF2 (red/green) and IKZF1 (gold). In 11% of nuclei both copies of IKZF1 are 595 
deleted. This clone subsequently acquires the IGH-CRLF2 translocation in a further 596 
83% of cells. 597 
(B) For patient 2017 a total of 211 abnormal nuclei at diagnosis were scored for probes 598 
to CRLF2 (red/green) and CDKN2A/B (gold) and PAX5 (aqua). The earliest abnormal 599 
clone detected has loss of a single copy of CDK2NA/B and PAX5 suggesting P2RY8-600 
CRLF2 is a sub-clonal event. This clone acquired P2RY8-CRLF2 in a further 70% of 601 
nuclei.  602 
 603 
 604 
 605 
 606 
 607 
 608 
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Figure 3. Multiple colour FISH showing examples of parallel evolution in (A-E) P2RY8-609 
CRLF2 (F) IGH-CRLF2 patients driven by reiterative CNAs within the same genes 610 
• Leukaemic sub-clone percentages for the diagnostic samples are indicated 611 
next to each clone and only include sub-clones above the 8% cut off. 612 
• Dashed lines present possible alternate routes to final sub-clone. It is likely that 613 
one sub-clone was not competitive enough and the other acquired the 614 
additional abnormality to continue evolving.  615 
• Dotted clone with “?”: presumed but undetected founder clone. 616 
(A) For patient 12200 a total of 269 abnormal nuclei at diagnosis were scored for 617 
probes to CRLF2 and CDKN2A/B. Two independent clones evolved from an 618 
undetectable founder clone either losing both copies of CDKN2A/B in 19% or acquiring 619 
the P2RY8-CRLF2 fusion in 16%. The major clone encompassing 65% of nuclei was 620 
observed to have both abnormalities from the previous two independent clones with 621 
an additional copy of CRLF2, which usually indicates the presence of an additional sex 622 
chromosome.  623 
(B) For patient 3173 a total of 58 abnormal nuclei at diagnosis were scored for probes 624 
to CRLF2 and IKZF1. Two independent clones evolved from an undetectable founder 625 
clone either losing a single copy of IKZF1 in 10% or the formation of P2RY8-CRLF2 in 626 
45%. A clone was observed to have evolved from either previous clone by gaining the 627 
P2RY8-CRLF2 fusion or losing a single copy of IKZF1, respectively.  628 
(C) For patient 4954 a total of 50 abnormal nuclei at diagnosis were scored for probes 629 
to CRLF2, IKZF1 and CDKN2A/B. The earliest clone detected harboured the P2RY8-630 
CRLF2 fusion with loss of a single copy of CDKN2A/B in 18%. Two independent clones 631 
evolved from this population either losing a single copy of IKZF1 in 30% or losing the 632 
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second copy of CDKN2A/B in 20%. The major clone encompassing 32% of nuclei was 633 
observed to have evolved from either previous clone by losing a second copy of 634 
CDKN2A/B or losing a single copy of IKZF1, respectively.  635 
(D) For patient 20753 a total of 50 abnormal nuclei at diagnosis were scored for 636 
probes to CRLF2, IKZF1 and PAX5. The earliest abnormal clone detected harboured the 637 
P2RY8-CRLF2 fusion with loss of a single copy of IKZF1 in 18% of nuclei. Two 638 
independent clones evolved from this population either losing the second copy of 639 
IKZF1 in 18% or doubling up the derived chromosome X to give two copies of P2RY8-640 
CRLF2 in 20%. This latter clone evolves further to lose a single copy of PAX5 in 20% 641 
and the second copy of IKZF1 in a further 24%. 642 
(E) For patient 5817 a total of 120 abnormal nuclei at diagnosis were scored for probes 643 
to CRLF2 and IKZF1. Two independent clones evolved from an undetectable founder 644 
clone. A signal pattern indicative of a rearrangement of CRLF2 (1R1G1F) in the 645 
presence of a single copy of IKZF1 was observed in 15% of cells. P2RY8-CRLF2 alone 646 
(FISH signal pattern 1R0G1F) was observed in an independent clone of 28%. This clone 647 
evolved to lose a single copy of IKZF1 in 52% followed by doubling up the derived sex 648 
chromosome to give two copies of P2RY8-CRLF2 in 21%.  649 
(F) For patient 21572 a total of 152 abnormal nuclei at diagnosis were scored for 650 
probes to CRLF2, IKZF1 and PAX5. Two independent clones evolved from an 651 
undetectable founder clone with different signal patterns for the CRLF2 652 
rearrangements. A signal pattern indicative of a rearrangement of CRLF2 (1R1G1F) 653 
was observed in 13% of cells in the presence of a single copy of IKZF1. IGH-CRLF2 alone 654 
was observed in an independent clone of 13%. The signal pattern observed in these 655 
cells was 1R0G1F, which in conjunction with a split IGH FISH signal pattern, suggests 656 
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the cells have an IGH-CRLF2 translocation and a deletion on the derived sex 657 
chromosome involved in the translocation. This clone evolves to lose a single copy of 658 
IKZF1 in 43% followed by loss of a single copy of PAX5 in a further 31%. 659 
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Figure 4. Sub-clonal architecture demonstrated by single cell analysis 681 
• Sub-clone percentages for the diagnostic samples are indicated next to each 682 
clone. 683 
• The blue triangle and orange square denote groups of clonal abnormalities 684 
including SNVs and CNAs. 685 
• Those sub-clones identified in the primary mouse spleen (S) and bone marrow 686 
(BM) are indicated using black arrows. Where secondary mice were tested; S-687 
S indicates spleen cells and S-BM, bone marrow cells.  688 
• Where stated, alterations were tracked by either patient specific fusion and 689 
mutation assays or generic copy number assays.  690 
• Gene copy numbers, where appropriate are indicated next to the gene name. 691 
(A) Non-DS-ALL patient 11543 - In the diagnostic sample 310 cells were successfully 692 
screened. Bulk diagnostic cells engrafted in three mice, the spleen and bone marrow 693 
(250 cells from each) were investigated from one mouse. At diagnosis the IGH-CRLF2 694 
translocation is observed on a background of clonal abnormalities (including loss of 695 
IKZF1) in 40% of cells with disruption of the second copy of IKZF1 in a further 48% of 696 
cells. No abnormalities were detected in 8% of cells. ^ Indicates both copies of IKZF1 697 
are disrupted. All clones were observed in cells isolated from the spleen with the two 698 
most frequent clones being observed in the bone marrow.   699 
 (B) Non-DS-ALL patient 21819 - In the diagnostic sample 296 cells were successfully 700 
screened. Bulk diagnostic cells engrafted in three mice and were serially transplanted. 701 
We investigated the spleen and bone marrow from one primary mouse (229 and 237 702 
cells respectfully) and one secondary mouse (76 and 221 cells respectfully). This 703 
leukaemia presented at diagnosis with a linear sub-clonal architecture characterised 704 
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by multiple aberrations; the deletion of IKZF1 was sub-clonal (96% of cells). The bulk 705 
sub-clone represented 89% of cells and harboured a P2RY8-CRLF2 fusion. This sub-706 
clone was observed across primary and secondary mice (S) in cells harvested from 707 
both the spleen and bone marrow. Primary mice also harboured the smaller sub-708 
clone. 709 
(C) DS-ALL patient 19599 - In the diagnostic sample 257 cells were successfully 710 
screened. Bulk diagnostic cells engrafted in three mice, the spleen and bone marrow 711 
(229 and 237 cells respectively) were investigated from one mouse. At diagnosis three 712 
independent subpopulations evolved from a backbone of clonal aberrations (which 713 
included loss of IKZF1 and a IGH-CRLF2 translocation). A small clone observed in 2% of 714 
cells acquired biallelic loss of IKZF1. Two further clones acquired unique independent 715 
IKZF1 mutations each then fostering additional alterations; one losing a single copy of 716 
BTLA and gaining a TOP3A mutation (13% of cells) followed by the acquisition of a JAK2 717 
mutation (54% cells); the other acquired another independent JAK2 mutation (4% of 718 
cells) followed by a GNB1 mutation (27%). This was the only clone to be detected in 719 
the mouse spleen and bone marrow cells from the mouse. ^ In those cells with an 720 
IKZF1 mutation, only the mutant signal was present, confirming IKZF1 copy number 721 
loss and mutation of the remaining copy. 722 
 (D) DS-ALL patient 11538 - In the diagnostic sample 324 cells were successfully 723 
screened. Bulk diagnostic cells engrafted in three mice, the spleen and bone marrow 724 
(243 and 240 cells respectively) were investigated from one mouse. At diagnosis two 725 
independent clones evolved from a very complex backbone of aberrations (including 726 
loss of IKZF1 and a P2RY8-CRLF2 fusion). A small clone was characterised by disruption 727 
of the second copy of IKZF1 alone (7% of cells) compared to the bulk clone which 728 
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acquired 5 further mutations and then disruption of the second copy of IKZF1 (57% of 729 
cells). ^ Indicates both copies of IKZF1 are disrupted. All clones were observed in the 730 
cells harvested from mouse spleen and bone marrow. The small clone characterised 731 
by disruption of the second IKZF1 allele was the major clone appearing in the mice.  732 
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Figure 4. Sub-clonal architecture demonstrated by single cell analysis
